Recovery Kernel

[redacted]

[redacted] — [redacted]

[redacted] [redacted] [redacted] [redacted] (walkthrough) [redacted]. [redacted] DNA [redacted]. [redacted] [redacted] [redacted] [redacted]. [redacted] [redacted] [redacted].

⚠ [redacted]

[redacted]-[redacted] [redacted] [redacted] - [redacted], [redacted] [redacted] [redacted]. [redacted], [redacted] [redacted].

[redacted]: **14416 or 1800-89-14416** [redacted] [redacted] [redacted]. [redacted]: **112** [redacted]. [redacted], **(GABRB3-**[redacted] [redacted]**) GABA-**[redacted] **—** [redacted]. [redacted], [redacted], [redacted] [redacted].

[redacted] [redacted] [redacted] [

[illegible]

[illegible]: [illegible], [illegible] DNA [illegible], [illegible]? [illegible], [illegible].

- [illegible] **1 — [illegible]. [illegible]-[illegible] $\rightarrow$ [illegible] VCF [illegible] $\rightarrow$ [illegible]. [illegible], [illegible]-[illegible].**
- [illegible] **2 — [illegible]. MTHFR ([illegible]), COMT ([illegible]), CYP2D6 ([illegible]), GABRA2/GABRB3 [illegible] ([illegible]), [illegible] OPRM1/DRD2 [illegible]. [illegible], [illegible].**
- [illegible] **3 — [illegible]. [illegible]. [illegible].**
- [illegible] **4 — [illegible]. [illegible] (stimulant) [illegible], [illegible] (dissociative) [illegible]. [illegible]: [illegible], [illegible], [illegible].**
- [illegible] **5 — [illegible], [illegible] — [illegible], [illegible].**
- [illegible] **6 — [illegible] AI [illegible]. [illegible], [illegible] AI [illegible], [illegible].**

> [illegible]
>
> **[illegible], [illegible], [illegible]. [illegible] — [illegible] — [illegible], [illegible].**

[illegible] 1 — [illegible]

1[illegible]. [illegible]: [illegible] → VCF → [illegible]

[illegible]: [illegible] (whole-genome sequence) [illegible] VCF [illegible], [illegible], [illegible]. [illegible]:

[illegible]	[illegible]	[illegible]
30× [illegible] ([illegible], [illegible],	[illegible]; [illegible] VCF [illegible] - [illegible]. ~$200–400, [illegible].	[illegible]. VCF [illegible] -

□□□□□□□	□□□ □□□□ □□□ □□□□□□□□	□□□□□
□□□□□□□□□□□□□□□.□□□□)		□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□□.
□□□□□□□□□□□ SNP □□□□□□ (23andMe, □□□□□□□□□□□□□)	MTHFR, COMT, DRD2, □□□□□□ CYP □□□ □□□□□ ~700k □□□□-□□□□□□□□ SNP □□ .txt □□□□□□.	□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□. VCF□□ □□□□□□□□ □□□□□, □□□□ □□□□□□□□□□□□□□□ □□□□□□□□ □□□□. □□□□□□□□ □□□□ (□□□□□) □□□□ □□□□□□□□□□□ (~$12) □□ □□□□□□.
□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ (□□□□□□□□, □□□□ □□□□□□□□)	□□□□□□□□□-□□□□□□ CYP2D6/2C19/3A4 □□□□□□, □□□□□□□□ □□□□□□ □□□□□□.	□□□□□/□□□□□□ □□□□ □□□□ □□□□□□ □□□□□ □□□□; □□□□□□ □□□□□□□□ □□□□ WGS □□□□□□□□□ □□□□□ □□□□□.
□□□□ □□□□□□□□□ □□□□□□□□□ (□□□□□□□□□□□, B12, □□□□ □□□□ □□□□ □□□□□□)	□□□□□□□□ US □□□□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□.	□□□□□□□□□ □□□□□□□□□□. □□□□□□□□□□□□ □□□□□□ □□□□ □□□□□□□□□ □□□□□□□.

□□□□□□□□□ **+** □□□□□□: **VCF** □□□□□□ □□□□□□□□□ □□□□□□ □□□□□□□□□□, □□□ **~16** □□□□□□□□ **(**□□□□□□□□□□□□□□□□□□, □□□□-□□□□□□, □□□□□□□□-□□□□□□, □□□□□□□□□□□□□□□□□, □□□□□□-□□□□□□□□□□□□□ □□□□□ □□□□□□□□**)** □□□□□□□□□ □□□□□□□□□. □□□□□□□ □□□□□□□□□, □□□ □□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□□□. □□□□□□□ □□□□□□□ □□□□□□ □□□□□□□□ □□□□: □□□□□□□□□□ — □□□□□ □□□□□ □ □□□□□□□□□□ □□□□□□□ — □□□□ □□□□□□.

□□□□□□ □□□□□□□ □□□□□: □□□□ □□□□□ □□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□, □□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□. **CYP2D6** □□□□□□ **FDA** □□□□□□ **60+** □□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□ **-** □□□ □□□□ □□□□□□ □□□□ □□□□□□□□□ **favor** □□□□, □□□□□□□□□□□ □□□□□□□□□ □□□□□□.

□□□□ □□□□ □□□□□□□□□□□□□□□□□: □□□□ □□□□□□□□ □□□□□□□

□□□□ □□□□□□□□□□□□□□□. □□□□□□□ □□□□□□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□□□□□□□□□□ □□□□□□-□□□□□□ (□□□□□□□□ 1 □□□□□ □□□□□□□ 2/3 , □□□□□□□□□□ □□□□□□□□□□ 06 □□□□□ GABA □□□□□□□□□□ □□□□□□□□□-□□□□□□□ □□□□□) □□□□. □□□ □□□□□□□□□□□□□ □□□□□□□□ — □□□□□□□ □□□□□□, □□□□□ □□□□□□□□□□□□, □□□□□□ □□□□□ □□□□□□ □□□□□□□□□□ — □□□□□□□□□ □□□□ □□□□□□ 15 □□□□□□□□□□ □□ □□□ □□□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□□. □□□ □□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□ 60–80% □□□□ □□□□□□□□□□□□; □□□□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□. □□□ □□□□□□□ □□□□□□, □□□□□ □□□□□□ □□□□ — □□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□.

□□ 2 — □□□ □□□□□ □□□□□□□□□□ □□□□□□

□□□ □□□□□□□□□□ □□□□□□□; □□□□□□ □□□□□□□. □□□□□□ □□□□□□ □□□□□□□□, □□□ □□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□ □□□ □□□□□□□□□□□□□ □□□□□.

□□□□□□□□ 1 — MTHFR (□□□□□□ □□□□□□□)

□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□□□□□□□□ □□□□ □□□□□□□□□□□□□□□□□. □□□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□. MTHFR □□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□ — □□□ □ □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□, □□□□□□ □□□□□□□ 40% □□□□□ □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□ □□□□□□□.

□□□□□□	□□□□□□	□□□ □□□ □□□□□□□□□□□□□
□□/□□ (□□□□□□□ □□□□□)	~100% □□□□□□□□□□.	□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□; □□□□□□□ □□□□□□□□□□ □□□□□□□□.
C/T (□□□□□□□□□□□□□)	~60–65% □□□□□□□□□□.	□□□□□□□ □□□□□ □□□□□□ □□□□□□□□□□□, □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□.
T/T (□□□□□□□□□□)	~30–40% □□□□□□□□□□; □□□□□□□□□ □□□□□□□□.	□□□□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□ - □□□ □□□□□□□ □□□□□□□□, □□ □□□□□□□.
□□□□□□□□□ □□□□□ (C/T + A1298C A/C)	□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□; T/T □□□ □□□□□□□□□□□□□□□□□□.	□□□□□□□ □□□□□ □□/□□ □□ □□□□□□□□□□□□□.

MTHFR □□□□□□□□□ □□□□□□□□□□□□□

□□□□□□ **T** → □□□□□□□□□ □□□□□□□ □□□□□□□□□ **(**□□□□□□□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□□□□□□□□□□□□**)** □□□□□□□□□□□□□. □□□□□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□□□□□; □□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□, □□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□ □□□□□□□□□□□. □□□□□□□□□ □□□□□□□. □□□□□□□□□□□□□□□ **/ L-**□□□□□□□□□□□□□□□ **/ 5-MTHF / Quatrefolic** □□□□□□□□□□□□□□□.

□□□□□□□□ 2 — COMT (□□□□□□□□□□□□ □□□□□□□□: □□□□□□□ □□□□□□□□ □□□□□/□□□□□□□)

□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□ □□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ — □□□□□ □□□□□□□□□ □ □□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□□□□. (□□□□□□□□□□ □□□□□□□□□□□ Met/Met □□□□□□□□ 'Worrier' □□□□□□ 'Sage' □□□□□□□□□□□ □□□□□□□□□□□□□□□□□; □□□□ □□□□□□□□□□.)

□□□□□□	□□□□□□□□□□	□□□□□□□ □□□□□ □□□□□□ □□□□□□□□□□□□□□□□ □□□□□□
Val/Val	□□□□□□□□□□□ - □□□□□□□□□□□ □□□□□□□□□□□□□	□□□□□□□□□ □□□□□□□□□; □□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□. □□□□□ □□□□□□□ □□□□□□□□□□□. □□□□□□□□□ □□□□□, □□□□□□□, □□□□□□,

[illegible]	[illegible]	[illegible]
		[illegible].
[illegible]/[illegible]	[illegible] / [illegible] — [illegible]	[illegible]. [illegible]. [illegible], [illegible], [illegible] - [illegible].
Val/Met	[illegible]	[illegible]; [illegible].

[illegible]: [illegible] (Warrior)[illegible], [illegible], [illegible] (Sage) [illegible], [illegible].

[illegible] 3 — CYP2D6 ([illegible])

[illegible]. [illegible], [illegible] — [illegible] '[illegible]' [illegible].

[illegible]	[illegible]	[illegible]
[illegible] (PM)	[illegible]. [illegible]/[illegible] [illegible]. [illegible].	[illegible]. [illegible]. Naloxone [illegible].
[illegible] (IM)	[illegible].	[illegible]-[illegible].
[illegible] (NM)	[illegible].	[illegible].
[illegible] (UM)	[illegible]; [illegible].	[illegible]. [illegible].

[illegible] 4 — GABRA2 / GABRB3 ([illegible])

[illegible]-[illegible], [illegible]. GABRA2 [illegible] - [illegible] '[illegible]' [illegible]. [illegible]; [illegible]. [illegible], [illegible] - [illegible].

[illegible]	[illegible]	[illegible]
GABRA2 [illegible] (rs279858 T-[illegible]) — ~15–20%	[illegible]. [illegible], [illegible]	[illegible]/[illegible] '[illegible]'[illegible]. [illegible]-[illegible]. [illegible]

[illegible]	[illegible]	[illegible]
	[illegible].	[illegible].
GABRA2 [illegible]-[illegible] — ~30–35%	[illegible] GABA [illegible].	[illegible]; [illegible].
GABRB3 [illegible]	[illegible]; [illegible].	[illegible]/[illegible] - [illegible]. [illegible], [illegible].

[illegible]-[illegible]. [illegible], [illegible]. [illegible] GABRA2 [illegible]-[illegible] — [illegible].

[illegible]: GABRA2 [illegible] — [illegible], [illegible], [illegible]. [illegible]: [illegible] ([illegible], [illegible], [illegible], [illegible]), [illegible], [illegible].

[illegible] 5 — OPRM1 [illegible] DRD2 ([illegible])

- **OPRM1 A118G. G-[illegible] (AG/GG) [illegible] Naloxone [illegible] — [illegible].**
- **DRD2 Taq1A ([illegible]). A1 [illegible] ~30% [illegible] D2 [illegible] — [illegible], [illegible]. [illegible]: [illegible] '[illegible],' [illegible]-[illegible] — [illegible], [illegible]. [illegible] (UMP + DHA + CDP-[illegible]) [illegible].**

□□ 3 — □□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□

□□□□□ - □□□ □□□□□□□ □□□□□□□□. □□□ □□□□□□□□□□□□ □□□□ □□□□□□ □□□□□□□, □□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□. □□□□□□ □□□ □□□□□ □□□□□□□ □□□□□□□ □□□□□□□.

□□□□□□ □□□□□□□□	□□□□□□□□	□□□ □□□ □□□□□□□□□□□□ & □□□□□□ □ **kaldı□□**
□□□□□□ □□□□□□ □□□□□ □□□□□□□ - MTHFR T/T + COMT Met/Met	□□□□□□ □□□□□□□□ + □□□□□□□□□ □□□□□□□□	□□□□□□□□□ □□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□. □□□□ □□□□□□□□□□□/□□□□□□□□/□□□□□ □□□□□□□□ □□□□□□□□□□, □□□□□□□□□ □□□□. □□□□□□□: methylfolate 15mg, magnesium 800mg, SAMe 800mg, theanine, □□□□□□□ □□□□□□□□.
□□□□□ □□□□□□□□□ □□□□□□ - MTHFR T/T + COMT Val/Val	□□□□□□ □□□□□□□□ + □□□□□□□□□ □□□□□□□□□□	□□□□□□□□□, □□□□□□□□, □□□□□□ □□□□□. □□□□□□□□ □□□□□ '□□□□ □□□□□□□□□ □□□□□□□□' □□□□□□ □□□□□□ □□□□□□□□. □□□□□□: methylfolate 7.5mg, □□□□□□□□, □□□□□□, □□□□□□□□□□□, □□□□-□□□□□ □□□□□□□□, □□□□□□□□.
□□□□□□□□□ - CYP2D6 PM/UM + MTHFR/COMT	□□□□ □□□□□□□□□□□□□□□ □□□□□□ + □□□□□ □□□□□	□□□□□□□□□□□□□□□ '□□□□□□□' □□□□□ □□□□□ .□□□□□□□□ □□□□□□□□ □□□□□□□ (□□□□□□□□ CYP2D6 □□ □□□□□□□□□). □□□□□□□: □□□□ □□□□□□□□□ □□□□□□□; Naloxone□□ □□□□□□□□□□.
□□□□□□□□ □□□□□□□□ — GABRA2 + COMT Val/Val	□□□□□□□ + □□□□□□□ □□□□ □□□□□□□□□□	□□□□□□□□□□ □□□□□□ □□□□ □□□□□□□□□□□; □□□□ □□□□ □□□□□□ □□□□□□ □□□□□□□□□□. □□□□□□□: □□□□□ □□ □□□□ □□□□□□□ + □□□□□ □□□□□□ □□□□□□□□□ □□□□□ + □□□□□□□□ □□□□□ □□□□□.
□□□□□□ □□□□□□ - GABRA2 + COMT □□□□/□□□□	□□□□□□□ + □□□□□□□□□ □□□□□-□□□□□□ □□□□□□□□	□□□□□ □□□□□ □□□□□□□□□□. □□□□□□□: □□□□ □□□ □□□□□ + □□□□□ □□□□□□□□□; □□□□□ □□□□□□□/□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□□□.
□□□□□□□□□□□□-□□□□□□□□□□□□ — GABRA2 + MTHFR T/T	□□□□□□□ + □□□□□ □□□□ □□□□□□□	□□□□ □□□□□□□ □□□□ □□□□□ □□□□: □□□□□□□ □□□□□□□□□ □□□□ □□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□□. □□□□ □□□□□□□ □□□□ □□□□□□□.

□□□ □□□□□□□□ □□□□□□

□□ □□□□□□□ □□□□□□□ □ □□□□ □□□□□□□□□ □□□□□□□□: **MTHFR-□□□** → □□□□ □□□□□□□ □□□□□□□□□. **COMT Val/Val →** □□□□ □□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□. **COMT Met/Met →** □□□□□□□ □□□□ □□□□□□□□□ □□□□□□□ □□□□□□□□. **GABRA2 →** □□□□□□□□□□□□□□□. **CYP2D6** □□□□□□□ □□□□ → □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□ **Naloxone** □□ □□□□□□□□□□□□. **DRD2 A1 →** □□□□□□ □□□□□□□

□□□□□□□ □□□□□□□□□	□□□□□□□□□	□□□ □□□ □□□□□□□□□□□□□ & □□□□□□□ □ **kaldı□□**
□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□. □□□□□ **4–5** □□ □□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □ □□□□□□□□.		

□□ 4 — □□□□□□□□□□□ □□□□□

□□□ □□□□□□□ □□□□□□□□ □□□□□□ □ □ □□□□□□□ □□□□□ □□□□□□□: □□□ □□□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□□□ □□□□□□□□ □□□□□□□□□□□□, □□□□□□□□ □□□□□ □□□□□□□□□□□ □□□ □□□□□□□□□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□□□□. □□□□ □□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□ □□□□ □□□ □□□□□ □□□□□□□□ — □□□□□□□□□□ Step 2–3 □□□□□□□□□ □□□□□□□□□□□ □□□ □□□□□□□□□□□□ □□□□□□□□□□.

□□□□□□□□ □□□□□□ □ □ — □□□□□□ (□□ □□□□□□□□□)

□□□□□□□□□: □□□□ 3–4× □□□□ □□□□□□□□□□□□□□□□. □□□□□□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□ — □□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□ □□□□□□/□□□□□ □□□□□□ □□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□. □□□□□□□ □□□□□ □□□□□□□□□□□□□□□□ □□□□□, □□□□□□□□□□□ □□□□□□□□ □□□□□, □□□□□ □□□□□□□□□□ □□□□□□□□□□ (anhedonia) □□□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□□□□□.

- □□□□□□□ □□□□□□ □□□□□ □□□□□□□□□: **COMT Val/Val, □□□□□□□ + MTHFR T/T, □□□□□□□□□□□□□ + DRD2 A1;** □□□□□□□□□□□□□-□□□□□□ □□□□□□ □□□□□ **GABRA2** □□ □□□□□□□□□□.
- □□□□□□□□□ □□□□: □□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□□ - □□□□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□□ □□□□□□□, □□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ , □□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□. □□□□□-□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□□□, □□□□□□□□□ □□□□□□□ □□□□□.
- □□□□□□/□□□□□□□□□□: □□□□□□ □□□□□□□□□ □□□□□□ □□□□□; **(□□□□□□□□□□□□□)** □□□□□□□□□ □□□□□□□□□; □□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□.
- □□□□□□ □□□□□□□□□□: □□□□□□ □□□□□□□□ □□□□□□ - □□□□□□ □□□□□□, □□□□□, □□□□□□□□□ □□□□□□□□. □□ □□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□ □ □□□□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□.

□□□□□□□□□ □□□□□□ □□ — □□□□□□□□ (□□□□□□□□□□□□□ □□□□□□□□□□□□)

□□□□□□□□□□: □□□□□□□□□□□□□/□□□□-□□□□□□□□□□ □□□□□□□□□ NMDA □□□□□□□□□□□□□□. □□□□ □□□□□□□□□□□□□□□□-□□□□□□-□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□, □□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□, □□□□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□.

- □□□□□□□□□ □□□□□□□□: □□□□□□□□ □□□□□□□□□□□□ - □□□□□□□□□□□□□, □□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□, □□□□□ □□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□. □□□ □□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□ □□□□□□ □□□□: □□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□.
- □□□□□□□□□ □□□□: □□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□□ **+ COMT** □□□□□□□; □□□□□□□□□□□□□□□□/□□□□□□□□□□□□□ □□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□ **NAC.** □□□□□□□□□□□□□ □□□□□□□□ □□□ □□□□□□□□□ □□□□□□□□□□□-□□□□□□□□□□□□□□ □□□□□□ □□□□□, □□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□□, □□□ □□□□□.
- □□□□□□□□□□□□□ □□□□□□□□□: □□□□□□□□□□ □□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□ □□□□□□ □□□□□□ □□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□ **—** □□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□□, □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□.

□□□□□□□□□ □□□□□□ C — □□□□□□□□ (□□ □□□□□□□□□□ □□□□ □□□□□□□□□□)

□□□□□□□□□: 7-□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□ □□□□□□□□ mu-□□□□□□□□□□ □□□□□□□□□□. □□□□□□□□ □□□□□□□□□□ □□□□ — □□□□□□□, □□□□□□□□□□□, 12–24 □□□□ □□□□□□□□□. □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□□□ □□□□□□□ □□□□□ / □□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□, □□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□□□□.

- □□□□□□□ □□□□□□ □□□□□ □□□□□□□□□: **COMT Met/Met, □□□□□□□ + MTHFR T/T; OPRM1 □□□□□□ CYP2D6** □□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□.
- □□□□□□/□□□□□□□□□ — □□□□□□□□ □□□□□: □□□□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□□, □□□□□□□□ □□□□□ □□□□□□□ □□□□□, □□□□□□ **ER** □□ □□□□□ **MAT** □□□□□□ □□□□□ □□□□ □□□□□□□□□□□□□□□□□□. **OPRM1 G-**□□□□□□□□ □□□□□□, □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□. **DLPA** □□□□□□□□□□ □□□□□□ **5–10%** □□□□□□□□□□ □□□□□□□□□□□□ □□□□□□□.
- □□□□□□□□□ □□□□□□□□□□□□□□□□: □□□□□ □□□□□□□□□□ — □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ **methylfolate, magnesium, SAMe, theanine;** □□□□□□ □□□□□□□ □□□□□□□□□□□□ □□□□□□□ □□□□□ **DLPA.** □□□□□□□□ □□□□□□ **CYP** □□□□□□□ □□□□□□□ □□□□□ □□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□ — □□□□ □□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□□□□□□□□.

□□□□□□□ '□□□□□□ □□ □□□□□□□□□□□□□ □□□□□□□□□' □□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□?

□□□□□□□□ □□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□□□□□□□; **DNA** □□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□. □□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□ □□□□□□□ **(Warrior)** □□□□□□ □□□□□□□ □□□□□□ □□□□□□□□□□□ □□□□□□□ **(Depleted Worrier)** □□□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□. □□□□□□□ □□□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□. □□□□□□□□□-□□□□□, □□□□□□□□-□□□□□□ □□□□□□□□□ — □□□□□□□ □□ □□□□□□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□ □□□□□□□ □□□□□□.

[illegible] 5 — [illegible], [illegible] [illegible] [illegible] [illegible]

[illegible]- [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] — [illegible] [illegible] ([illegible] 1-3)

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] 8 [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ([illegible], [illegible]) [illegible].

[illegible] [illegible] ([illegible])

- [illegible]-: 1[illegible] [illegible] [illegible] → 8 [illegible] 7.5–15[illegible] (MTHFR [illegible] [illegible] [illegible])
- ([illegible] B12) 5,000mcg · [illegible] [illegible] 400–800[illegible] · P-5-P (B6) 50[illegible] · TMG 1,000[illegible]
- [illegible]-3 (EPA/DHA) 2–3[illegible] · NAC 1,200[illegible] ([illegible] [illegible] [illegible]) · [illegible] [illegible] 1,000[illegible]

[illegible] [illegible]-[illegible] (COMT Val/Val)

- [illegible]-[illegible] 1,000–2,000[illegible] · [illegible] [illegible] 200–400[illegible] · [illegible] 500[illegible] [illegible] 2[illegible] · [illegible] [illegible] 400[illegible]

[illegible]/[illegible] [illegible] [illegible] (COMT [illegible]/[illegible])

- [illegible]-[illegible] 400[illegible] [illegible] 2[illegible] · SAMe 800[illegible] · [illegible] 1,000[illegible] · [illegible] [illegible] [illegible]

[illegible]-[illegible] [illegible]-[illegible] (GABRA2/GABRB3 [illegible])

- [illegible] [illegible] 600–800[illegible] [illegible] ([illegible] [illegible]) · [illegible]-[illegible] 400[illegible] [illegible] 2× · [illegible] 1,000[illegible] · [illegible] 3[illegible] [illegible] [illegible] · [illegible] [illegible]- [illegible] ([illegible]). [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible]/[illegible], [illegible], KSM-66 [illegible].

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] ([illegible] 3-6)

[illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible] [illegible]:

- **[illegible]/[illegible]: MAT [illegible]; [illegible] 1-2 [illegible] [illegible] 5-10% [illegible]; DLPA 500mg [illegible] 2[illegible]; [illegible] [illegible] [illegible] [illegible] [illegible].**
- **[illegible]/[illegible]: [illegible] ([illegible] [illegible] [illegible]); [illegible] [illegible] 2,000[illegible] [illegible] 2×; [illegible]-[illegible] [illegible] [illegible] [illegible].**
- **[illegible]/[illegible] ([illegible] [illegible] GABRB3-[illegible] [illegible]): [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible]. [illegible] [illegible], [illegible] [illegible]. GABA [illegible] ([illegible], [illegible], [illegible], [illegible]); -[illegible] [illegible]/[illegible].**

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] ([illegible] 6–12)

□□□□□□□□□□-□□□□□□□□□□ □□□□□□ □□□□□□□□□, □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□□□□□□□□□□□ □□□□□□□□□□□□□ (BDNF, D2 □□□□□□□□, □□□□□□□□□□□□ □□□□□□□□□□□□□□□) — □□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□ □□□□□.

	□□□□□□□□□□ (Val/Val)	□□□□□/□□□□□□□ □□□□□□ □□□□□□□□ (□□□□□/□□□□□)	GABRA2 (□□□□□□□□□□)
□□□□□□□ □□	HIIT, □□□□□□□□□□□□□□□□, □□□□□□□□ □□□□□□□□, □□□□□ □□□□□□	□□□□□, □□□□□-2 □□□□□□□□□□, □□□□□□□□□□□□□□, □□□□□□□□□□□□	□□□□□□□□□□ □□□□□□ (□□□□□□□□□□/□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□), □□□□□-2 □□□□□□□□□□, 4-7-8 □□□□□□□□□□□□
□□□□□□□ □□□□□□□□	□□□□□□□□ □□□□□ □□□□□□□□□□ → □□□□□□□□□□□	HIIT/□□□□□□□□□□□□ □□□□□ → □□□□□□□□□□□□ □□□□	□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□
□□□□□□□□	□□□□□ □□□□ □□ □□□□□□	□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□□ □□□□□□□	□□□□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□□□; □□□□□□□□ □□□□□□□□ □□□□□□ □□□□□□□ □□□□□

□□□□□□□ □□□□□□□□□ - □□□□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□ □□□□□ **('□□□□□□□ □□□□□□□□□□')**

□□□□□□□ □□□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□□□□. □□ □□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□, □□□□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□: '□□□□□□□□□□ **2** □□□□□□□□□ □□□□□□□ □□□□□□□□□ □□□□□□□□□□□□□□□□□□□' □□□□□□ **4–8** □□□□□□□□□ □□□□□□□□□□; '**8-**□□□□□□ □□□□□□ □□□□□□□□□' □□□□□□ **2–5** □□□□□□□□ □□□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□ **12–16** □□□□□□□ □□□□□□□□□. □□□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□.

□□□□□□□: □ □□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□□□□□□□, □□□□□ □□□□□□□□□ □□□□□□□ □□□□□□□ □□□□□□□□□□□□□. □□□□□□□□□□-□□□□□□□ □□□□□□□□□□□□□□, □□□□□□□□□□ □□□□□□□□□ □□□□□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□ □□□□□□ — □□□□□□□□ □□□□□□□□□□□ □□□□□□□ □□□□□□□ **NAC,** □□□□□□□□□□ □□□□□□□ □□□□□□ **(**□□□□□□□□□□ □□□□□□□ □□□□□□□□□□□□□**) AMPA/BDNF** □□□□□□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□□□□ □□ □□□□□□ □□□□□□. □□□□□□□□□ □□□□□□□□□□□□□. □□□ □□□□□ □□□□□□□□□□ □□□□□□□□□□□□□. □□□ □□□□□□□□ □□□□□ — □□□ □□ □□□□□□□ □□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□□□.

[illegible] 6 — [illegible] AI [illegible]

[illegible] AI [illegible] — [illegible]. [illegible], [illegible] AI [illegible]. [illegible], [illegible]; [illegible], [illegible], [illegible], [illegible].

=== [illegible] ===

GENETIC VARIANTS: MTHFR C677T ___ · MTHFR A1298C ___ · COMT Val158Met ___ (Warrior/Balanced/Sage) · CYP2D6 ___ (PM/IM/NM/UM) · CYP2C19 ___ · GABRA2 ___ · GABRB3 ___ · OPRM1 ___ · DRD2 ___

[illegible]: [illegible] ___ ([illegible] <10) · B12 ___ ([illegible] >400) · [illegible] ___ ([illegible] 40–60)

[illegible]: [illegible]([illegible]) ___ · [illegible] ___ · [illegible] ___ · [illegible] ___

[illegible]: ___ [illegible] ([illegible] + [illegible]): ___

[illegible]: ___

=== [illegible] ===

[illegible]

- **[illegible]: ' [illegible], CPIC/FDA [illegible] — [[illegible]][illegible], [illegible], [illegible] CYP [illegible], [illegible]?'**
- **[illegible]: [illegible] [[illegible]] [illegible] [[illegible]] [illegible]; CYP2D6 [illegible] [[illegible]]; [illegible] [illegible]/[illegible] — [illegible]? [illegible]? [illegible]?**
- **[illegible]: '[illegible], [illegible], [illegible], [illegible] — [illegible], [illegible], [illegible], [illegible], [illegible]?'**
- **[illegible]: [illegible]/[illegible]/[illegible]/[illegible]/[illegible] [illegible] 1–10 [illegible] — [illegible], [illegible], [illegible], [illegible]? [illegible].**

[illegible]

AI [illegible], [illegible]. [illegible], [illegible]. [illegible], [illegible].

[illegible] → [illegible].
[illegible] → 14416 or 1800-89-14416. [illegible] → 112.

AI [illegible] [illegible], [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible].

[illegible] [illegible] [illegible] **(**[illegible] [illegible] [illegible] [illegible]**),** [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]- [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] **AI** [illegible] [illegible] [illegible]. **DNA** [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible].